# BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct06205706/  
OnCo record `nct06205706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by BioInvent International AB, active and no longer recruiting.

## Summary

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06205706 by BioInvent International AB, with 35 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2027-07-14. Interventions recorded: BI-1910, Pembrolizumab. Conditions listed: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06205706
- Phase: 1/2
- Setting: Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- Sponsor: BioInvent International AB
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT06205706: https://clinicaltrials.gov/study/NCT06205706

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/)

---
JSON: https://onco.cc/api/v1/entities/nct06205706.json